Ongoing and Associated Studies
Other than the I3, there are multiple IBD-related studies that are happening at Penn that you may be eligible for such as:
Study of a Prospective Adult Research Cohort with IBD (SPARC-IBD)
Partnering with the Crohn's and Colitis Foundation of America (CCFA), the University of Pennsylvania among several other national sites will aim to enroll 7,000 patients in order to create a national biobank and repository of clinical data, colonic biospsies, blood, and stool from patients diagnosed with inflammatory bowel disease. Patients will be asked to donate samples and provide clinical data on a quarterly basis as well as allow study staff to access their medical records.
MiMIC- Microbial metabolites in IBD & CDI
The goal of our project is to better understand why patient’s with IBD may be more susceptible to infection with Clostridioides difficile, a gut pathogen that can cause symptoms ranging from moderate to severe diarrhea to toxic megacolon and death. We will be studying the metabolic environment present during C. difficile infection in patients with Inflammatory Bowel Disease to identify novel biomarkers that can aid in the detection of this infection and guide treatment decisions.
The Checkpoint-Inhibitor Induced Intestinal Inflammation and IBD Immunology Initiative (CI7)
Immune-checkpoint inhibitors are a class of medications that have been approved for the treatment of several cancers, including melanoma, lung cancer and kidney cancer. A possible side effect of these medications includes diarrhea and inflammation of the bowel. This gut inflammation is referred to as checkpoint inhibitor induced colitis (CIIC). The purpose of this research study is to improve our understanding of how the immune system and the gut interact when CIIC occurs. The study protocol is similar to the I3 study in that we will be collecting tissue biopsies and blood samples for analysis.
Stress and IBD
The I3 team is seeking out IBD patients who are willing to donate time and samples to help researchers better understand the effects of stress on inflammatory bowel disease; in particular, how disease activity changes with stress levels. Participating includes having patients fill out stress surveys and providing blood and tissue samples, similar to the I3 study.
Immunogenicity of herpes zoster subunit vaccine among ulcerative colitis patients treated with tofacitinib and other immunosuppressive regimens
In collaboration with Pfizer Pharmaceuticals, University of Pennsylvania is doing research to measure how the immune system responds to Shingrix, the new shingles vaccine, in patients with ulcerative colitis who are treated with different medications. Shingrix is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older. If you agree, you will have blood drawn before, 1 month after, and 6 months after receiving the Shingrix vaccine to measure your body’s immunity to shingles. You will be in the study between 8 to 12 months if you decide to stay for the whole study.
CORE-IBD w/ the CDC
To address health disparities and increase IBD awareness through provider and patient education and dissemination of study findings and other evidence-based practices to researchers, clinicians, and patients. Educate healthcare providers about IBD diagnosis, management, and outcomes to improve time to diagnosis and initiation of treatment, particularly among diverse and marginalized populations. Educate patients on the natural history of IBD, goals of care, self-management, preventative healthcare and surgical care with specialized educational materials for issues of importance to marginalized populations
Partnering with the Crohn's and Colitis Foundation of America (CCFA), the University of Pennsylvania among several other national sites will aim to enroll 7,000 patients in order to create a national biobank and repository of clinical data, colonic biospsies, blood, and stool from patients diagnosed with inflammatory bowel disease. Patients will be asked to donate samples and provide clinical data on a quarterly basis as well as allow study staff to access their medical records.
MiMIC- Microbial metabolites in IBD & CDI
The goal of our project is to better understand why patient’s with IBD may be more susceptible to infection with Clostridioides difficile, a gut pathogen that can cause symptoms ranging from moderate to severe diarrhea to toxic megacolon and death. We will be studying the metabolic environment present during C. difficile infection in patients with Inflammatory Bowel Disease to identify novel biomarkers that can aid in the detection of this infection and guide treatment decisions.
The Checkpoint-Inhibitor Induced Intestinal Inflammation and IBD Immunology Initiative (CI7)
Immune-checkpoint inhibitors are a class of medications that have been approved for the treatment of several cancers, including melanoma, lung cancer and kidney cancer. A possible side effect of these medications includes diarrhea and inflammation of the bowel. This gut inflammation is referred to as checkpoint inhibitor induced colitis (CIIC). The purpose of this research study is to improve our understanding of how the immune system and the gut interact when CIIC occurs. The study protocol is similar to the I3 study in that we will be collecting tissue biopsies and blood samples for analysis.
Stress and IBD
The I3 team is seeking out IBD patients who are willing to donate time and samples to help researchers better understand the effects of stress on inflammatory bowel disease; in particular, how disease activity changes with stress levels. Participating includes having patients fill out stress surveys and providing blood and tissue samples, similar to the I3 study.
Immunogenicity of herpes zoster subunit vaccine among ulcerative colitis patients treated with tofacitinib and other immunosuppressive regimens
In collaboration with Pfizer Pharmaceuticals, University of Pennsylvania is doing research to measure how the immune system responds to Shingrix, the new shingles vaccine, in patients with ulcerative colitis who are treated with different medications. Shingrix is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older. If you agree, you will have blood drawn before, 1 month after, and 6 months after receiving the Shingrix vaccine to measure your body’s immunity to shingles. You will be in the study between 8 to 12 months if you decide to stay for the whole study.
CORE-IBD w/ the CDC
To address health disparities and increase IBD awareness through provider and patient education and dissemination of study findings and other evidence-based practices to researchers, clinicians, and patients. Educate healthcare providers about IBD diagnosis, management, and outcomes to improve time to diagnosis and initiation of treatment, particularly among diverse and marginalized populations. Educate patients on the natural history of IBD, goals of care, self-management, preventative healthcare and surgical care with specialized educational materials for issues of importance to marginalized populations
|
|